Hemotune
hemotune AG is a Swiss company specializing in innovative blood purification technology. Originating from ETH Zurich, it aims to develop breakthrough solutions for critical illnesses like sepsis, combining biomedicine, nanotechnology, and engineering. The company's mission is to create revolutionary intervention strategies to improve patient outcomes and save lives, with a focus on precision medicine and immunological aspects of diseases.
Industries
Nr. of Employees
small (1-50)
Patents
Products
HemoSystem (magnetic bead-based blood purification system)
An extracorporeal blood purification system that integrates magnetic bead capture technology and system hardware to remove multiple pathological targets from blood as a precision therapy for critical illness.
HemoSystem (magnetic bead-based blood purification system)
An extracorporeal blood purification system that integrates magnetic bead capture technology and system hardware to remove multiple pathological targets from blood as a precision therapy for critical illness.
Services
Provision of clinical advisory input, protocol guidance and study planning through an established clinical advisory board and clinical affairs leadership.
End-to-end activities for design, prototyping, production and servicing of sterile and non-sterile blood purification devices and associated components.
Provision of clinical advisory input, protocol guidance and study planning through an established clinical advisory board and clinical affairs leadership.
End-to-end activities for design, prototyping, production and servicing of sterile and non-sterile blood purification devices and associated components.
Expertise Areas
- Blood purification and extracorporeal therapies
- Magnetic nanoparticle and colloidal nanomaterials
- Medical device design and hardware development
- Regulatory compliance for medical devices (ISO 13485)
Key Technologies
- Magnetic bead-based separation
- Coated colloidal magnetic nanoparticles
- Magnetic particle detection
- Extracorporeal reactor/hardware for hemoperfusion
News & Updates
Announcement of Harald Casebourne Stock's appointment as President of the Board of Directors.
Funding to support clinical trials of the HemoSystem blood purification platform.
Awarded for innovation and impact in blood purification technology.
The company has achieved ISO 13485 certification, marking a milestone in medical device quality management.
Recognition for innovative research and development in blood purification technology.
Announcement of Harald Casebourne Stock's appointment as President of the Board of Directors.
Funding to support clinical trials of the HemoSystem blood purification platform.
Awarded for innovation and impact in blood purification technology.
The company has achieved ISO 13485 certification, marking a milestone in medical device quality management.
Recognition for innovative research and development in blood purification technology.